RightFit
Not yet recruitingPhase not listed

Effect of Acetominophen an Gait Fatigue in Multiple Sclerosis

Effect of Antipyretics in Gait Fatigue in Multiple Sclerosis

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 65 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests whether acetaminophen, a medicine that lowers fever, helps people with multiple sclerosis (MS) walk longer before getting tired. Participants will take acetaminophen at one visit and a placebo (a pill with no active medicine) at another visit, one week apart. At each visit, they will walk on a treadmill while wearing a safety harness.

The goal of this observational study is to compare the impact of an antipyretic, acetaminophen to a placebo on gait fatigue in persons with multiple sclerosis (MS). The primary question this study is asking is the following: will the antipyretic effects of acetaminophen result in less gait fatigue in persons with MS? Participants will be asked to come for two sessions over a 1 week period. In the first week, subjects will be blind-randomized into either the acetaminophen or placebo group. They will then undergo a test to determine their gait speed by performing two 25 foot walks at their best comfortable pace. The walks will be 1 minute apart. The average speed from those 2 walks will be obtained. Subjects will then take either the acetaminophen or the placebo. Following a 45 minute rest period they will then get on a treadmill and will walk at the previously determined speed for as long as they can. Walking will stop if the subject can no longer maintain the speed or if they wish to no longer continue. The subjects will wear a safety harness at all times during the walk to prevent falls. Heart rate and core body temperature will be measured via skin sensors. One week later the subjects will return and repeat the procedure but this time in the opposite condition. Subjects who took the acetaminophen will take the placebo and subjects who took the placebo will take the acetaminophen. The difference between distance walked in the 2 conditions will be compared.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Have a definite MS diagnosis that you report to the study team.
  • Be 18 to 65 years old.
  • Be able to walk for 2 minutes without stopping, with or without a walking aid.
  • Provide blood test results from the past 6 months to 1 year showing normal liver and kidney function.

Who can't join

  • Have a current or recent MS flare-up, when symptoms get worse.
  • Have had a bad reaction to medicines that lower fever.
  • Have used steroids recently.
  • Have a condition other than MS that affects walking.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * A definitive MS diagnosis confirmed by self-report, * The ability to walk for 2 minutes continuously with or without assistive device ---Age 18-65 * Provide a blood test within the last 6 months to 1 year reflecting normal liver and renal profile (normal liver enzymes and normal creatinine level). Exclusion Criteria: * Any current or recent exacerbations * Any adverse reaction to antipyretics * Recent use of steroids * Any non-MS conditions that interfere with walking performance.

Study sites (1)

NY